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Introduction
　Myelodysplastic syndromes（MDS）are a heterogeneous group of clonal hematopoietic 
stem cell disorders characterized by persistent peripheral cytopenia with morphological and 
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Abstract : Myelodysplastic syndromes are a heterogeneous group of clonal 
hematopoietic stem cell disorders characterized by persistent peripheral 
cytopenia with morphological and functional abnormalities of hematopoietic 
cells.  Mast cells inltrate into or around tumor tissues and play a role in 
remodeling of the stromal microenvironment, contributing to tumor progression. 
Increased mast cell numbers are associated with brosis, angiogenesis and a 
poor prognosis in human carcinomas.  The aim of this study was to determine 
whether mast cell infiltration contributes to myelofibrosis or angiogenesis in 
myelodysplastic syndromes.  We evaluated the correlation between mast cell 
density and the extent of myelofibrosis and angiogenesis in myelodysplastic 
syndromes.  Fifty bone marrow biopsies taken from patients with a diagnosis 
of myelodysplastic syndromes were examined.  Grading of myelobrosis was 
evaluated by silver impregnation staining.  Mast cell density and microvessel 
density were evaluated by immunohistochemistry.  Human mast cells have 
been divided into two phenotypes.  We designated a tryptase-positive mast cell 
as MCT and a chymase-positive mast cell as MCTC.  Microvessels were identi-
ed by CD34-positive endothelial cells.  Microvessel density and the extent of 
myelobrosis were signicantly greater in patients with high MCT and MCTC 
density compared to those with low MC density.  Based on this, we suggest 
that the presence of high mast cell numbers is associated with myelobrosis 
and angiogenesis in myelodysplastic syndromes.
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functional abnormalities of hematopoietic cells.  Patients with MDS often have bone marrow
（BM）hypercellularity with an increased risk of transformation into acute myeloid leukemia
（AML）1）.  The pathogenesis of MDS is a multi-step process, including a series of genetic 
mutations within hematopoietic stem cells and abnormalities of BM microenvironment. 
Components of the BM microenvironment include macrophages, broblasts, vascular endothe-
lial cells and mast cells（MCs）.
　MCs are derived from precursors of the hematopoietic lineage and complete their dif-
ferentiation in peripheral tissues2）.  These cells have been implicated in the pathogenesis 
of a variety of chronic inammatory diseases.  MCs contain various biochemical mediators 
in cytoplasmic granules, including histamine, heparin, tryptase, chymase, and cytokines such 
as interleukin（IL）-4, IL-5, IL-6 and IL-8.  The release of these substances from MCs in 
inammatory lesions is thought to play an important role in acceleration of the inamma-
tory process, angiogenesis and brosis.  Human MCs have been divided into two phenotypes 
based on protease content : a tryptase-positive, chymase-positive phenotype, termed MCTC, 
and a tryptase-positive, chymase-negative phenotype, termed MCT3）.  Both the MCTC and 
MCT phenotypes are present in almost all human tissues.
　Elevated MC numbers in human carcinomas, including hepatocellular carcinoma, cholangio-
carcinoma4）, oral squamous cell carcinoma5）, and pulmonary adenocarcinoma6）, are associated 
with brosis, angiogenesis and a poor prognosis.  MCs may also be associated with brosis 
and angiogenesis in lymphomas.  Molin and colleagues found a higher number of MCs in 
nodular sclerosis classical Hodgkin lymphoma than in other types of Hodgkin lymphoma, 
and patients with higher MC inltration have reduced relapse-free survival 7）.  In B-cell non-
Hodgkin’s lymphoma, the MC density is correlated with microvessel density（MVD）, and 
both densities increase in parallel with increasing grade of malignancy8）.  Fukushima and 
colleagues reported that MCs are associated with brosis in diffuse large B-cell lymphoma 9）. 
An increase in the MC count is also seen in MDS 10, 11）.  There are some reports that MC 
numbers often increase in MDS with myelobrosis 12） and the extent of angiogenesis cor-
relates with the number of MCs in MDS 13）.  In this study, we evaluated the correlation of 
MCT and MCTC density with the extent of myelobrosis and angiogenesis in MDS, to inves-
tigate whether MC inltration contributes to myelobrosis and angiogenesis in MDS and to 
clarify the alteration of BM microenvironment in MDS.
Methods
Patients
　We examined parafn-embedded trephine BM biopsies from 72 patients with a diagnosis 
of MDS at Showa University Hospital（Tokyo, Japan）from 1997 to 2007.  Patients pro-
vided informed consent at the time the BM examination was performed.  BM trephine 
biopsies were obtained from the posterior iliac crest, and aspiration samples were obtained 
simultaneously for cytology.  BM smears, prepared without anticoagulant, were fixed and 
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stained by the May-Giemsa method.  Twenty-two patients were excluded from the study 
due to insufcient materials or inadequate follow-up, leaving 50 patients for analysis.  The 
patients included 33 men and 17 women, ranging in age from 40 to 90 years（mean 72.2 
years）.  Their survival period ranged from 2 to 49 months（mean 12 months）.  Peripheral 
blood（PB）cell counts and BM smear counts were also obtained, including the percentage 
of myeloblasts in the PB and BM, the type and degree of dysplasia, the presence of ring 
sideroblasts, and karyotype.  Based on the BM myeloblast count, number of PB cytopenias 
and karyotype, the patients were stratied using the International Prognostic Scoring System
（IPSS）14） into four risk groups : low risk（score 0 ; n＝7）, intermediate-1（score 0.5-1.0 ; n＝
17）, intermediate-2（score 1.5-2.0 ; n＝19）, or high risk（score ≥2.5 ; n＝7）.  Patients were 
classied according to the French-American-British（FAB）15） and World Health Organization
（WHO）1） criteria.  They were divided into FAB subgroups as follows : refractory anemia
（RA）, n＝11 ; RA with ring sideroblasts（RARS）, n＝6 ; RA with excess blasts（RAEB）, 
Fig. 1.　Myelofibrosis and immunohistochemical staining of mast cells（MCs）and microvessels in bone 
marrow（BM）. MCT was detected as a tryptase-positive MC and MCTC was detected as a chymase-
positive MC. BM microvessels were identied as CD34-positive endothelial cells. Both MCT and 
MCTC increased with extent of myelobrosis and microvessel density（MVD）. MF-0 ;（a）HE,（b）
silver impregnation,（c）tryptase,（d）chymase,（e）CD34 : MF-1 ;（f）HE,（g）silver impregnation,
（h）tryptase,（i）chymase,（j）CD34 : MF-2 ;（k）HE,（l）silver impregnation,（m）tryptase,（n）
chymase,（o）CD34 : MF-3 ;（p）HE,（q）silver impregnation,（r）tryptase,（s）chymase,（t）CD34
（×400）.
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n＝19 ; RAEB in transformation（RAEB-t）, n＝8 ; AML arising from MDS, referred to as 
MDS overt leukemia（MDS-OL）, n＝3.  Patients were further classied according to WHO 
criteria as follows : refractory cytopenia with unilineage dysplasia（RCUD）, actually RA, n＝
1 ; RARS, n＝1 ; refractory cytopenia with multilineage dysplasia（RCMD）, n＝14 ; RAEB-
1, n＝14 ; RAEB-2, n＝6 ; MDS associated with isolated deletion of 5q, n＝1 ; and AML 
with myelodysplasia-related changes, n＝10.  Although chronic myelomonocytic leukemia has 
recently been removed from the denition of MDS, 3 cases were included in the study to 
examine possible differences between chronic myelomonocytic leukemia and MDS subtypes. 
As controls, BM biopsies from 5 patients with no evidence of lymphoma cell inltration, 
performed for diagnostic purposes as a part of staging procedures for classical Hodgkin 
lymphoma（n＝1）and non-Hodgkin lymphoma（n＝4）, were also evaluated.
Bone marrow analysis
　The specimens were xed in 10％ buffered formalin, decalcied in 10％ buffered EDTA
（pH 7.2）, and embedded in parafn.  The parafn-embedded tissue sections were stained 
using hematoxylin and eosin（HE）, Giemsa stain, naphthol-ASD-chloroacetate, and silver 
impregnation for histological investigation.  Semiquantitative evaluation of BM cellularity was 
performed with a scoring system based on cell numbers in normal BM : 0, no increase in 
comparison with the normal state ; ＋1 / -1, mild to moderate increase / decrease ; ＋2 / -2, 
marked increase / decrease 16）.  Immunohistochemical staining was performed on the same 
tissue sections.  Examination of the biopsies was carried out independently by two investiga-
tors unaware of the patients’ diagnosis and clinical data.  Patient samples were taken at the 
time of initial diagnosis.  In the cases that progressed to AML（n＝14）, we examined the 
nine BM biopsies at the time of overt leukemia development if they were available.
Myelobrosis grading
　Grading of myelofibrosis（accumulation of reticulin and collagen fibers）followed the 
semiquantitative scoring system 17）: MF-0, scattered linear reticulin with no intersections
（cross-overs）corresponding to normal BM ; MF-1, loose network of reticulin with many 
intersections, especially in perivascular areas ; MF-2, diffuse and dense increase in reticulin 
with extensive intersections, occasionally with only focal bundles of collagen and / or focal 
osteosclerosis ; and MF-3, diffuse and dense increase in reticulin with extensive intersections 
with coarse bundles of collagen, often associated with signicant osteosclerosis.
Immunohistochemistry
　Formalin-xed, parafn-embedded specimens of BM biopsies were examined by immuno-
histochemical staining procedures.  We used monoclonal antibodies against tryptase（10D11, 
Novocastra, Newcastle-upon-Tyne, UK ; diluted 1 : 150）to detect MCT, chymase（CC1, MBL, 
Nagoya, Japan ; diluted 1 : 100）to detect MCTC18）, and CD34（NU-4A1, Nichirei, Tokyo, 
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Japan ; diluted 1 : 50）to detect blood vessels identied by CD34-positive endothelial cells. 
Tissue sections were deparafnized with xylene, rehydrated in a series of graded alcohols, 
and then immersed in 3％ H2O2 to quench the endogenous peroxidase activity.  For CD34 
staining, sections were then subjected to microwave antigen retrieval in citric acid buffer at 
pH 7.0 for 30 min at 98℃.  After incubation with primary monoclonal antibodies for 90 
min at room temperature, immunohistochemical staining was performed using an Envision 
Kit（DakoCytomation, Glostrup, Denmark）.  Diaminobenzidine was used for color develop-
ment, and hematoxylin was used for counterstaining.
Mast cell counts
　The number of tryptase-positive and chymase-positive MCs in the specimens were quanti-
ed using a computerized morphometry system（WinROOF ver.  5.01, Mitani Corp., Tokyo, 
Japan）.  MCT and MCTC densities were expressed as the absolute number of tryptase-
positive or chymase-positive MCs per 1 mm2 of hematopoietic area in BM biopsies.
Quantication of microvessel density
　CD34 is a useful antigen for assessing intratumor angiogenesis in solid tumors and meets 
the high quality requirements for BM angiogenesis research.  Blood vessels were dened by 
CD34-positive endothelial cells forming a structure with a clearly discernible lumen.  This 
denition is important to discriminate blood vessels from CD34-positive myeloid progeni-
tors.  Myeloid stem cells are also CD34-positive, but these cells can be excluded by their 
morphology, even if highly abundant 19）.  Slides were rst scanned at 100×  magnication and 
3 areas with abundant microvessels were chosen and dened as “hot spots”.  The number 
of microvessels in each of these hot spots was then determined at 400×  magnication.  The 
nal MVD（microvessels per eld at 400×  magnication）was determined by taking the 
average of 3 separate visual counts.  Large vessels and vessels in the periosteum or bone 
were not counted.
Statistical analysis
　All statistical analyses were performed using StatView software（ver. 5.0, SAS Institute 
Inc. Raleigh, NC, USA）.  Patient characteristics and MC density were compared using the 
Chi-squared test with Fisher’s exact test.  Comparisons between two groups were performed 
using the Mann-Whitney U-test and comparisons among more than three groups were made 
with the Kruskal-Wallis test.  P values ＜0.05 were considered to be statistically signicant.
Results
　Clinical and pathological parameters of the fty MDS patients investigated in this study 
are shown in Table 1.  More tryptase-positive MCs than chymase-positive MCs were detected 
in the paraffin-embedded MDS specimens（MCT : 2.27±3.50 / mm2 versus MCTC : 1.19±
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Table 1.　Clinical and histological ndings of patients with myelodysplastic syndromes 
at the initial diagnosis and the time of overt leukemia
no. Age
（years）





（ / ×400 eld）
Initial diagnosis
1 74 F Low RCUD（RA） RA -1 13.46 13.69 MF-2 17
2 62 M Low RCMD RA 0 4.92 1.47 MF-2 6
3 74 F Int-1 RCMD RA -2 0.13 0.13 MF-1 9.33
4 85 M Int-1 RCMD RA -1 1.04 0.96 MF-0 8.33
5 58 M Int-1 RCMD RA 0 0 0 MF-1 12.33
6 60 M Int-2 RCMD RA ＋1 0.29 0.22 MF-2 10.33
7 68 F Int-1 RARS RARS 0 4.98 3.23 MF-1 8
8 69 M Low RCMD RARS -2 6.32 4.07 MF-0 12
9 74 M Int-1 RAEB-1 RAEB ＋1 2.21 0.80 MF-2 20
10 80 M Int-1 RAEB-1 RAEB -1 1.92 2.40 MF-1 20.33
11 80 F Int-1 RAEB-1 RAEB -2 0 0 MF-0 15
12 80 M Int-1 RAEB-1 RAEB ＋1 0.21 0.07 MF-1 11
13 83 M Int-1 RAEB-1 RAEB -1 1.14 0.25 MF-0 8
14 73 M Int-1 RAEB-1 RAEB ＋2 0 0 MF-1 8.67
15 86 F Int-2 RAEB-1 RAEB -2 3.06 0.36 MF-1 10
16 86 F Int-2 RAEB-1 RAEB -1 0 0 MF-0 11.67
17 53 M Int-2 RAEB-1 RAEB -1 0.93 1.03 MF-2 17.33
18 69 M Int-2 RAEB-1 RAEB ＋1 0.20 0.07 MF-1 5.33
19 79 M Int-2 RAEB-1 RAEB 0 7.13 0.41 MF-2 10
20 76 F Int-1 RAEB-2 RAEB ＋2 7.58 3.83 MF-3 29.67
21 66 F Int-2 RAEB-2 RAEB ＋1 0.63 0 MF-1 5.67
22 74 M Int-2 RAEB-2 RAEB -1 0.98 0.22 MF-1 10.33
23 69 M Int-2 RAEB-2 RAEB ＋2 2.62 0.19 MF-1 11.33
24 50 M Int-2 RAEB-2 RAEB-t -1 1.20 0 MF-1 11.67
25 81 M High RAEB-2 RAEB ＋1 2.31 0.45 MF-2 3.67
26 73 F High AML-MDS RAEB-t -1 0 0 MF-1 11
27 62 M Int-2 AML-MDS RAEB-t -2 0.20 0.14 MF-0 10.67
28 90 M Int-2 AML-MDS RAEB-t -1 0.37 0.28 MF-0 7.67
29 40 M Int-2 AML-MDS RAEB-t -1 2.64 1.48 MF-1 21.67
30 77 M Int-2 AML-MDS MDS-OL ＋1 2.08 2.91 MF-2 11.67
31 62 M High AML-MDS RAEB-t -2 0.91 0 MF-2 13.67
32 69 F High AML-MDS MDS-OL ＋1 0.94 0.22 MF-1 4
33 87 F High AML-MDS RAEB-t 0 1.62 1.00 MF-1 0.67
34 71 M High AML-MDS RAEB-t -1 1.06 0.79 MF-1 13
35 77 M High AML-MDS MDS-OL ＋1 0.24 0.08 MF-1 6.33
36 64 M Low CMML CMML 0 0.75 0.52 MF-1 13
37 81 F Int-1 RCMD RA ＋2 1.16 0.88 MF-1 17.33
38 81 M Low RCMD RA ＋1 1.87 1.19 MF-1 11.67
39 62 F Int-1 RCMD RA ＋1 0.89 0.36 MF-1 3
40 63 M Int-2 RCMD RA 0 2.99 0.34 MF-1 11.67
41 80 F Int-1 RCMD RARS ＋2 17.87 14.17 MF-1 6.67
42 66 M Int-1 RCMD RARS 0 0.54 0 MF-0 12.33
43 65 M Int-2 CMML CMML 0 0.49 0.49 MF-1 4.33
44 84 M Low CMML CMML ＋1 0 0 MF-0 6.67
45 78 M Int-2 RAEB-1 RAEB 0 1.49 0.37 MF-2 1.67
46 73 F Int-2 RAEB-1 RAEB -1 2.78 0.29 MF-2 6.67
47 70 F Int-2 RCMD RARS -1 0 0 MF-0 6.33
48 84 M Int-1 RAEB-1 RAEB ＋2 8.94 0.17 MF-2 16.33
49 63 M Low 5q- RARS -2 0.45 0 MF-0 14.33
50 77 F Int-1 RCMD RA -2 0 0 MF-1 10.67
at the time of overt leukemia
37’ NA
38’ 0 0 0 MF-2 8
39’ ＋2 0.27 0.03 MF-0 3.67
40’ 0 9.22 0.24 MF-1 2.67
41’ 0 3.65 3.16 MF-2 5.33
42’ 0 0.12 0.12 MF-1 18.33
43’ NA
44’ -1 0.15 0.08 MF-0 14
45’ ＋2 0.87 0 MF-2 24
46’ -1 0.35 0.07 MF-0 6.33




IPSS : International Progonostic Scoring System, Int : intermediate, WHO : World Health Organization, FAB : French-American-British, 
MCT : tryptase-positive, chymase-negative mast cell, MCTC : tryptase-and chymase-positive mast cell, MVD : microvessel density, 
RCUD : refractory cytopenia with unilineage, RA : refractory anemia, RCMD : refractory cytopenia with multilineage dysplasia, 
RARS : RA with ring sideroblasts, RAEB : RA with excess blasts, RAEB-t : RAEB in transformation, 
AML-MDS : acute myeloid leukemia with myelodysplasia-related changes, MDS-OL : myelodysplastic syndromes overt leukemia, 
CMML : chronic myelomonocytic leukemia, 5q- : MDS associated with isolated del（5q）, NA : not available
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2.81 / mm2, P＝0.004）.  Morphologically, both round to oval MCs and spindle MCs were 
detected.  Qualitatively, we detected more round to oval MCs than spindle MCs.  The 
extent of myelobrosis and MVD were signicantly higher in patients with high MCT and 
MCTC densities（＞1.5 MCT / mm2 or ＞0.37 MCTC / mm2）than in those with low MCT 
density（myelofibrosis P＝0.018 ; MVD P＝0.041）or MCTC density（myelofibrosis P＝
0.027 ; MVD P＝0.007）.  The MCT density was higher in the high-brosis group（MF-2, 
MF-3）than in the low-brosis group（MF-0, MF-1）.  The MCTC density was also higher in 
the high-brosis group（MF-2, MF-3）than in the low-brosis group（MF-0, MF-1）.  The 
MCT and MCTC densities were higher in patients with high MVD（MVD ≥16 per 400× 
eld）than in patients with low MVD（MVD ＜16 per 400× eld）（Table 2）.  The MCT 
or MCTC density were not correlated with age, sex, IPSS classication, BM cellularity, sur-
vival period, presence of MDS-OL transformation, or time to transformation to MDS-OL. 
There was no signicant correlation between the grade of myelobrosis and MVD.  Neither 
FAB nor WHO classications of MDS were signicantly correlated with the MCT or MCTC 
density, the grade of myelobrosis or MVD.  Among the patients who progressed to AML, 
there was no signicant difference in the MCT or MCTC density, the grade of myelobrosis, 
or MVD before and after transformation to MDS-OL.
Discussion
　The BM microenvironment is regulated by stromal cells, including endothelial cells and 
macrophage-lineage cells.  The stromal microenvironment is composed of vessels, broblasts 
and several kinds of inflammatory cells, and it influences tumor growth and progression. 
MCs inltrate into or around tumor tissues and play a role in remodeling of the stromal 
microenvironment, which leads to tumor progression.  Human MCs are conventionally 
divided into two types depending on the expression of different proteases in their gran-
Table 2.　Density of mast cells in myelodysplastic syndromes











Number of MCs（ / mm2）（mean±SD）











Number of MCs（ / mm2）（mean±SD）
MCT : tryptase-positive, chymase-negative mast cell, 
MCTC : tryptase- and chymase-positive mast cell,
MCs : mast cells, MVD : microvessel density
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ules : the MCT type contains tryptase and is predominantly located in the lungs and small 
intestinal mucosa, whereas the MCTC type contains both tryptase and chymase and is pre-
dominantly found in connective tissue areas such as skin, heart, synovia and small intestinal 
submucosa2, 3）.  Tryptase is a serine protease and a mitogen and comitogen for broblasts 
and tracheal smooth muscle cells, while chymase is a chymotrypsin-like serine protease that 
converts angiotensin I to angiotensin II.  Angiotensin II stimulates broblast proliferation 
through activation of transforming growth factor-β19）.  These ndings suggest that both MC 
tryptase and MC chymase play important roles in the development of brosis in human 
disease.
　Horny and colleagues reported that the predominant BM MC type is MCTC in normal 
or reactive states, and MCT in neoplastic states such as MDS20）.  In our study, more 
tryptase-positive MCs than chymase-positive MCs were detected in MDS cases.  A few 
quantitative immunohistochemical analyses of the tissue distribution of MCT and MCTC have 
been published.  Terada and Matsunaga4） showed that the percentages of MCT and MCTC, 
approximately 20％ and 80％ respectively, were almost the same in normal liver, hepatocel-
lular carcinoma and intrahepatic cholangiocarcinoma.  Fukushima and colleagues9） reported 
a preponderance of MCT over MCTC, both in diffuse large B-cell lymphoma lymph nodes 
and in reactive lymph nodes.  However, the pathophysiological basis of the lack of chymase 
expression in MCs involved in MDS remains unknown.
　Myelofibrosis is present in approximately 10％ of MDS cases1）, and histopathological 
and clinical differences between brotic and non-brotic MDS have been reported.  BM 
cellularity, white blood cell counts, and the percentage of myeloblasts in PB and BM are 
signicantly higher in MDS with myelobrosis compared to MDS without myelobrosis 12）. 
In our study, however, the only signicant difference between MDS cases with and without 
myelobrosis was that the BM smear nucleated cell count was lower in high-brosis cases 
than in low-brosis cases.  The extent of the myelobrosis can be such that BM aspiration 
results in either “dry taps” or extremely scanty and non-representative aspirates, which may 
produce lower BM smear nucleated cell counts in MDS with myelobrosis.  A previous 
study linked myelofibrosis to a poor prognosis in terms of life expectancy and time to 
leukemic transformation21）, however Pagliuca and colleagues found relatively long survival in 
a series of 10 MDS patients with myelobrosis 22）, and Rios and colleagues did not nd a 
signicant correlation between myelobrosis and reduced survival23）.  Therefore, the relation-
ship between the occurrence of myelobrosis in MDS and survival is still controversial.
　MC density is also correlated with the extent of pathological angiogenesis, such as that in 
chronic inammatory diseases and tumors.  In our study, both the MCT and MCTC densities 
were higher in the high MVD group than in the low MVD group.  MCs contain many 
angiogenic factors, such as heparin and histamine, and a variety of cytokines and chemok-
ines, such as transforming growth factor-β, tumor necrosis factor-α, IL-8, basic fibroblast 
growth factor（also known as fibroblast growth factor-2）and vascular endothelial growth 
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factor13）.  Tryptase acts as a mitogen for broblasts, smooth muscle cells and epithelial cells, 
so tryptase released from MCs also plays an important role in neovascularization.
　Abnormal angiogenesis has been implicated in the pathogenesis of MDS, and increased 
MVD in the BM of patients with MDS has also been described24）.  We found no sig-
nicant correlation between MVD and clinico-histological parameters.  Some studies have 
reported increased MVD in hypercellular MDS than normocellular or hypocellular cases 25, 26）, 
however other studies found no significant correlation between MVD and BM cellular-
ity, PB counts, or percentage of BM myeloblasts 19, 24）.  Similarly, most studies have failed 
to show a significant correlation between MVD and prognostic factors, including overall 
survival, progression-free survival and IPSS score.  Ribatti and colleagues, however, showed 
that angiogenesis in MDS was correlated with total metachromatic and tryptase-positive MC 
counts and that microvessels and MC counts increased together with MDS progression 13）. 
In our study, there was no signicant correlation between MVD and MDS progression, how-
ever MCTC densities were higher in patients with high MVD, suggesting that MC chymase 
may play an important role in angiogenesis in MDS.
　The accumulation of MCs in different tumors has been documented.  Under normal 
conditions MCs are absent from the PB and they are rarely seen in BM 27）, and the number 
of MCs is lower than that of any other hematopoietic cells in BM, even in cases in which 
the BM MC count increases.  Increased numbers of BM MCs were found in 45（2.2％）
of 2000 BM specimens obtained from patients with hematologic disorders10）.  In our study, 
there was no signicant difference in MC density between MDS cases and controls, however 
our control samples were BM biopsies from patients with malignant lymphoma, which may 
be somewhat biased, even without inltration of lymphoma cells.
　Stem cell factor, which is produced mainly by stromal cells, is the principal growth fac-
tor for human MCs28）, while MCs also induce stem cell factor.  In MDS, levels of stem 
cell factor may increase as the period of ineffective hematopoiesis and cytopenia becomes 
longer.  Therefore, MCs may also increase with the period of cytopenia.  MCs induce vari-
ous biochemical mediators to promote brosis, while stem cell factor is produced by mainly 
broblasts.  Consequently, whether the increase of MCs contributes to the development of 
brosis or results from brosis is still a matter of discussion.
　Recently, Chiu and colleagues suggested that the fibrogenetic mechanism in systemic 
mastocytosis is most likely different from that of other BM neoplasms which are also associ-
ated with myelobrosis29）.  Systemic mastocytosis is a stem cell disorder characterized by a 
pathological accumulation of clonal MCs in one or more organ system.  The MC aggregates 
are accompanied by brosis.  In their study, there was no signicant expression of type IV 
collagen or laminin in BM of systemic mastocytosis, compared with primary myelobrosis 
or metastatic malignancy.  Normal BM MCs are reported to be round to oval in shape30）. 
Horny and colleagues reported round to oval shape MCs in many cases of MDS, while in 
the cases of mastocytosis, the MC shape showed variability ; spindle shaped cells were the 
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predominant cell type in most cases20）.  These differences in MC morphology may affect the 
different mechanisms of myelobrosis in MDS and systemic mastocytosis.  In our study, both 
round to oval MCs and spindle MCs were detected, but there were more round to oval 
MCs than spindle MCs.  From this, we infer that the increase in MC numbers in MDS is 
reactive, and not due to clonal proliferation.
　Based on the results of this study, we suggest that MCT and MCTC densities are cor-
related with the extent of myelobrosis and angiogenesis in MDS.  Evaluation of possible 
correlations between the outcome of patients with MDS and MC density and the extent of 
myelobrosis or angiogenesis will require a study with a larger series of cases.
Acknowledgments
　We thank Yoshiko Sasaki and Yosuke Sasaki of the Second Department of Pathology, Showa University School 
of Medicine, for their technical assistance in immunohistochemistry.  This work was supported in part by a Showa 
University Research Grant for Young Researchers.
References
1） Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW and Hellstrom-
Lindberg E : Myelodysplastic syndromes / neoplasms, overview. In : WHO Classification of Tumours of Hae-
matopoietic and Lymphoid Tissues. 4th ed, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, 
Thiele J and Vardiman JW（Eds）, IARC Press, Lyon, pp 88-93（2008）
2） Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L and Dammacco F : The role of mast cells in tumor angio-
genesis. Br J Haematol 115：514-521（2001）
3） Irani AA, Schechter NM, Craig SS, DeBlois G and Schwartz LB : Two types of human mast cells that have 
distinct neutral protease compositions. Proc Natl Acad Sci USA 83：4464-4468（1986）
4） Terada T and Matsunaga Y : Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarci-
noma. J Hepatol 33：961-966（2000）
5） Iamaroon A, Pongsiriwet S, Jittidecharaks S, Pattanaporn K, Prapayasatok S and Wanachantararak S : Increase 
of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med 32：195-199（2003）
6） Takanami I, Takeuchi K and Naruke M : Mast cell density is associated with angiogenesis and poor prognosis 
in pulmonary adenocarcinoma. Cancer 88：2686-2692（2000）
7） Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, Sundstrom C and Gunilla E : Mast cell inltration 
correlates with poor prognosis in Hodgkin’s lymphoma. Br J Haematol 119：122-124（2002）
8） Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L and Dammacco F : Angiogenesis and mast cell 
density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin’s 
lymphomas. Int J Cancer 85：171-175（2000）
9） Fukushima H, Ohsawa M, Ikura Y, Naruko T, Sugama Y, Suekane T, Kitabayashi C, Inoue T, Hino M and 
Ueda M : Mast cells in diffuse large B-cell lymphoma ; their role in brosis. Histopathology 49：498-505（2006）
10） Prokocimer M and Polliack A : Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, 
and lymphoproliferative disorders. Am J Clin Pathol 75：34-38（1981）
11） Yoo D and Lessin LS : Bone marrow mast cell content in preleukemic syndrome. Am J Med 73：539-542
（1982）
12） Marisavljevic E, Rolovic Z, Cemerikic V, Boskovic D and Colovic M : Myelobrosis in primary myelodysplastic 
syndromes. Med Oncol 21：325-331（2004）
13） Ribatti D, Polimeno G, Vacca A, Marzullo A, Crivellato E, Nico B, Lucarelli G and Dammacco F : Correlation 
of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia 16：
61Mast Cells in Myelodysplastic Syndromes
1680-1684（2002）
14） Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, 
Ohyashiki K, Toyama K, Aul C, Mufti G and Bennett J : International scoring system for evaluating prognosis 
in myelodysplastic syndromes. Blood 89：2079-2088（1997）
15） Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR and Sultan C, The French-
American-British（FAB）Co-operative Group : Proposals for the classication of the myelodysplastic syndromes. 
Br J Haematol 51：189-199（1982）
16） Thiele J, Kvasnicka HM, Schmitt-Graeff A, Kriener S, Engels K, Staib P, Ollig ES, Keller C, Fokkema S, 
Griesshammer M, Waller CF, Ottmann OG and Hansmann ML : Bone marrow changes in chronic myelog-
enous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571 : an immunohistochemical 
study on 75 patients. Histopathology 46：540-550（2005）
17） Thiele J, Kvasnicka HM, Facchetti F, Franco V, Walt J and Orazi A : European consensus on grading bone 
marrow brosis and assessment of cellularity. Haematologica 90：1128-1132（2005）
18） Irani AA, Bradford TR, Kepley CL, Schechter NM and Schwartz LB : Detection of MCT and MCTC types of 
human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibobodies. 
J Histochem Cytochem 37：1509-1515 （1989）
19） Lundberg LG, Hellstrom-Lindberg E, Kanter-Lewensohn L, Lerner R and Palmblad J : Angiogenesis in relation 
to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res 30：247-253（2006）
20） Horny HP, Greschniok A, Jordan JH, Menke DM and Valent P : Chymase expressing bone marrow mast cells 
in mastocytosis and myelodysplastic syndromes : an immunohistochemical and morphometric study. J Clin Pathol 
56：103-106（2003）
21） Maschek H, Georgii A, Kaloutsi V, Werner M, Bandecar K, Kressel M-G, Choritz H, Freund M and Hufnagl 
D : Myelobrosis in primary myelodysplastic syndromes : A retrospective study of 352 patients. Eur J Haematol 
48：208-214（1992）
22） Pagliuca A, Layton DM, Manoharan A, Gordon S, Green PJ and Mufti GJ : Myelobrosis in primary myelo-
dysplastic syndromes : a clinico-morphological study of 10 cases. Br J Haematol 71：499-504（1989）
23） Rios A, Canizo MC, Sanz MA, Vallespi T, Sanz G, Torrabadella M, Gomis F, Ruiz C and San Miguel JF : 
Bone marrow biopsy in myelodysplastic syndromes : morphological characteristics and contribution to the study 
of prognostic factors. Br J Haematol 75：26-33（1990）
24） Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brien S, Keating 
M, Freireich E and Albitar M : Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. 
Blood 96：2240-2245（2000）
25） Korkolopoulou P, Apostolidou E, Pavlopoulos PM, Kavantzas N, Vyniou N, Thymara I, Terpos E, Patsouris E, 
Yataganas X and Davaris P : Prognostic evaluation of the microvascular network in myelodysplastic syndromes. 
Leukemia 15：1369-1376（2001）
26） Stifter G, Heiss S, Gastl G, Tzankov A and Stauder R : Over-expression of tumor necrosis factor-alpha in bone 
marrow biopsies from patients with myelodysplastic syndromes : relationship to anemia and prognosis. Eur J 
Haematol 75：485-491（2005）
27） Udoji WC and Razavi SA : Mast cells and myelobrosis. Am J Clin Pathol 63：203-209（1975）
28） Metcalfe DD : Mast cells and mastocytosis. Blood 112：946-956（2008）
29） Chiu A, Nanaji NM, Czader M, Gheorghe G, Knowles DM, Chadburn A and Orazi A : The stromal composi-
tion of mast cell aggregates in systemic mastocytosis. Mod Pathol 22：857-865（2009）
30） Stevens EC and Rosenthal NS : Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in 
systemic mast cell disease. Am J Clin Pathol 116：177-182（2001）
［Received January 15, 2010 : Accepted January 22, 2010］
